WASHINGTON, DC (February 10, 2020)- The Association for Accessible Medicines (AAM), the trade association representing the manufacturers of generic and biosimilar medicines, announced today that Chester “Chip” Davis, Jr. is leaving the organization.
Jeffrey Francer, AAM Senior Vice President and General Counsel, will serve as interim CEO while the board determines a permanent replacement.
Association for Accessible Medicines Chairman of the Board Alok Sonig, CEO of US Generics and Global Head of Generics R&D & Biosimilars for Lupin Limited, issued the following statement on behalf of the AAM Board of Directors:
"It is with gratitude and respect that the Association for Accessible Medicines announces the resignation of Chip Davis as President and CEO. Chip's commitment, leadership and focus on patients took AAM to a higher level of effectiveness advocating for the U.S. generic and biosimilar industry. We greatly appreciate his service and wish him success with his future plans.
"On behalf of the Board of Directors, we are pleased to announce that Jeffrey Francer, AAM's Senior Vice President and General Counsel, will serve as Interim CEO. Since 2016, Jeff has built a formidable team that continues to successfully safeguard competition and protect patient access to safe, affordable FDA-approved generic and biosimilar medicines. The entire Board of Directors has great confidence in Jeff's ability to continue AAM's growing record of successful advocacy."
Mr. Francer added, "The generic drug and biosimilars industry owes Chip a debt of gratitude for his leadership and hard work on behalf of patients who are struggling with the high cost of health care. I am honored to continue to support the mission of AAM's member companies to enhance access to life-saving medicines and deliver great value to patients and taxpayers."
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 22 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.